This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Galantamine

Authoring team

Galantamine is primarily a cholinesterase inhibitor which is indicated in patients with mild to moderate Alzheimer's disease.

There is evidence that, in a mixed population of patients with probable vascular dementia or Alzheimer's disease and cerebrovascular disease, galantamine was more effective than placebo for improving cognitive ability and global functioning (1).

With respect to patient with Alzheimer's disease

  • clinicians, but not patients and caregivers, observed a significantly greater improvement in goal attainment among patients with mild to moderate Alzheimer's disease who were taking galantamine than among those who were taking placebo (2)

The summary of product characteristics must be consulted before prescribing this drug.

Reference:

  1. Lancet 2002 Apr 13;359(9314):1283-90
  2. CMAJ 2006;174:1099-105

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.